64 results on '"Wasserman, Todd"'
Search Results
2. The Growth of Academic Radiation Oncology: A Survey of Endowed Professorships in Radiation Oncology
3. Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)
4. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma
5. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04
6. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer
7. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison
8. Irradiation with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: final results of RTOG 80-05
9. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
10. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508
11. Neuropathy of nitroimidazole radiosensitizers: Clinical and pathological description
12. Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?
13. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: Based on rtog trial #79-15
14. Radiotherapy and chemotherapy in combined clinical trials: Problems and promise
15. Cost accounting in radiation oncology: A computer-based model for reimbursement
16. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: Report of an rtog prospective randomized trial
17. Lymphoma: Radiation therapy in lymphoma treatment
18. The late effects of toxicity scoring
19. The radiation therapy oncology group: An outline of clinical research activities
20. Large fraction irradiation with or without misonidazole in advanced non-oat cell carcinoma of the lung: A phase III randomized trial of the RTOG
21. Radiotherapy with or without misonidazole for patients with stage IIIB or stage IVA squamous cell carcinoma of the uterine cervix: Preliminary report of a radiation therapy oncology group randomized trial
22. Use of a colorimetric microtiter (mtt) assay in determining the radiosensitivity of cells from murine solid tumors
23. Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system
24. Radiation therapy for stage i and iia testicular seminoma
25. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer
26. Physician resource utilization in radiation oncology: A model based on management of carcinoma of the prostate
27. Cost benefit of emerging technology in localized carcinoma of the prostate
28. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: Results of the rtog dose escalating protocol
29. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique
30. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials
31. Analysis of prognostic factors in localized gastric lymphoma: The importance of bulk of disease
32. Initial pharmacology and toxicology of intravenous desmethylmisonidazole
33. Clinical trials of hypoxic cell sensitizers
34. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: Final report of rtog phase I/II study
35. Palliative radiation treatment of cutaneous mycosis fungoides—A dose response
36. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III–IV squamous cancers of the head and neck
37. Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug schedule
38. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus bcnu for treatment of malignant glioma after surgery; Preliminary results of an RTOG study
39. Final report of the phase i trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03
40. Accelerated fractionation radiation therapy for liver metastases: Selection of an optimal patient population for the evaluation of late hepatic injury in rtog studies
41. Non-Hodgkin's lymphomas following radiation therapy alone for Hodgkin's disease
42. When is a negative study not negative?
43. Assurance of high quality linac-based stereotactic radiosurgery
44. The radiation therapy oncology group: An update of clinical research activities
45. Evaluation of the bioavailability of misonidazole (NSC#261037) in capsule and tablet form and pharmacologic effects of daily dosage
46. Hypoxic cell radiosensitizers—present and future
47. Failure of misonidazole to improve outcome in advanced h&n squamous cancers
48. Protection by WR-2721 against experimentally-induced acute radiation retinopathy
49. Hypoxic cell radiosensitizers: illusion or elusion?
50. Hypofractionated radiotherapy with or without misonidazole for the treatment of brain metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.